3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 3
1
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Other hematologic neoplasm
2
Myeloid
2
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Abiraterone Acetate
1
Interventions
Docetaxel
77
Radiotherapy
73
Prednisone
66
Leuprolide
51
Goserelin
49
Gemcitabine
49
Cisplatin
48
bicalutamide
46
enzalutamide
43
Androgen Antagonists
36
pembrolizumab
32
Abiraterone Acetate
31
Mitomycin
29
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
28
Magnetic Resonance Spectroscopy
28
Carboplatin
27
Flutamide
25
Nivolumab
24
Triptorelin Pamoate
23
Sunitinib
23
apalutamide
22
Radiation
22
Doxorubicin
20
darolutamide
19
abiraterone
18
Gonadotropin-Releasing Hormone
18
cabozantinib
17
atezolizumab
16
Specimen Handling
16
Radiosurgery
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
BID protein, human
×
Genitourinary
×
Clear all
NCT06768255
2025-01-10
mCRPC
Fudan University
Phase 3
Not yet recruiting
400 enrolled